Apollomics (APLM) Competitors $18.43 +6.25 (+51.34%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. SLGL, XBIT, LITS, UNCY, RPTX, OKYO, CRVO, VTVT, INCR, and PMVPShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Sol-Gel Technologies (SLGL), XBiotech (XBIT), Lite Strategy (LITS), Unicycive Therapeutics (UNCY), Repare Therapeutics (RPTX), OKYO Pharma (OKYO), CervoMed (CRVO), vTv Therapeutics (VTVT), InterCure (INCR), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors Sol-Gel Technologies XBiotech Lite Strategy Unicycive Therapeutics Repare Therapeutics OKYO Pharma CervoMed vTv Therapeutics InterCure PMV Pharmaceuticals Sol-Gel Technologies (NASDAQ:SLGL) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk. Which has better valuation and earnings, SLGL or APLM? Sol-Gel Technologies has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.54M9.51-$10.58M-$1.23-31.97Apollomics$1.49M13.61-$53.86MN/AN/A Which has more risk and volatility, SLGL or APLM? Sol-Gel Technologies has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Do analysts recommend SLGL or APLM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals and insiders believe in SLGL or APLM? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is SLGL or APLM more profitable? Apollomics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -14.25%. Apollomics' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-14.25% -11.80% -9.39% Apollomics N/A N/A N/A Does the media favor SLGL or APLM? In the previous week, Sol-Gel Technologies had 2 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 2 mentions for Apollomics. Sol-Gel Technologies' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySol-Gel Technologies beats Apollomics on 6 of the 11 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.34M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E RatioN/A21.5785.3527.60Price / Sales13.61271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book4.1110.1413.016.76Net Income-$53.86M-$52.31M$3.30B$275.88M7 Day PerformanceN/A5.14%4.34%2.81%1 Month Performance213.22%14.68%9.49%9.24%1 Year Performance36.44%30.98%84.83%35.42% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.3879 of 5 stars$18.43+51.3%N/A+29.8%$20.34M$1.49M0.0045Analyst ForecastGap UpHigh Trading VolumeSLGLSol-Gel Technologies0.3184 of 5 stars$29.15+1.4%N/A+503.9%$81.33M$11.54M-23.7050News CoverageAnalyst ForecastXBITXBiotech1.0882 of 5 stars$2.66-1.1%N/A-60.9%$81.10M$4.01M-2.89100News CoveragePositive NewsAnalyst ForecastLITSLite StrategyN/A$2.42-4.7%N/AN/A$79.47MN/A-0.51100News CoveragePositive NewsAnalyst ForecastGap DownUNCYUnicycive Therapeutics2.2875 of 5 stars$4.36+5.1%$57.00+1,207.3%+32.5%$77.01MN/A-1.069Analyst ForecastRPTXRepare Therapeutics2.8005 of 5 stars$1.76+1.1%$4.50+155.7%-47.2%$75.61M$53.48M-0.68180Analyst ForecastOKYOOKYO Pharma2.9184 of 5 stars$2.00flat$7.00+250.0%+117.7%$75.22MN/A0.007Analyst ForecastShort Interest ↓CRVOCervoMed3.7554 of 5 stars$8.09+0.1%$19.29+138.4%-32.6%$74.83M$9.74M-3.104News CoverageAnalyst ForecastShort Interest ↓VTVTvTv Therapeutics1.6734 of 5 stars$23.45+2.2%$35.50+51.4%+51.6%$74.81M$1.02M-7.529INCRInterCure1.1698 of 5 stars$1.64+5.1%N/A-10.6%$74.74M$238.85M0.00350News CoverageAnalyst ForecastHigh Trading VolumePMVPPMV Pharmaceuticals2.7023 of 5 stars$1.40-3.4%$5.50+292.9%-4.4%$74.19MN/A-0.8950 Related Companies and Tools Related Companies Sol-Gel Technologies Competitors XBiotech Competitors Lite Strategy Competitors Unicycive Therapeutics Competitors Repare Therapeutics Competitors OKYO Pharma Competitors CervoMed Competitors vTv Therapeutics Competitors InterCure Competitors PMV Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
